TScan Therapeutics (TCRX) Share-based Compensation (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Share-based Compensation data on file, last reported at $2.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 27.8% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $10.8 million, a 2.02% decrease from a year earlier, with the FY2025 full-year figure at $18.8 million, down 21.67% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.5 million, up from $2.0 million in the prior quarter.
• Over the last five years, Share-based Compensation for TCRX reached as high as $3.4 million in Q1 2025 and fell as low as $984000.0 in Q1 2022.
• Historically, Share-based Compensation has averaged $2.0 million across 5 years, with a median of $2.0 million in 2024.
• On a YoY basis, Share-based Compensation climbed as much as 186.05% in 2022 and fell as far as 88.25% in 2022.
• Year by year, Share-based Compensation stood at $1.3 million in 2022, then climbed by 15.65% to $1.5 million in 2023, then soared by 80.93% to $2.7 million in 2024, then fell by 26.01% to $2.0 million in 2025, then climbed by 22.76% to $2.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.5 million in Q1 2026, $2.0 million in Q4 2025, and $3.0 million in Q3 2025.